Shanghai, China – Virogin Biotech Ltd. ("Virogin") has been named 2018 Ernst & Young Fudan China’s Most Promising Enterprise, recognized within the ‘Health Reimagined’ category (Press release, Virogin Biotech, OCT 15, 2018, View Source [SID1234532328]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hosted by global professional services firm Ernst & Young and Fudan University’s School of Management, these 8th annual awards identified prominent companies and future industry leaders that exhibit a commitment to innovation, sustained high growth, and potential to strengthen the economic development of China. At the industry awards ceremony, Virogin was recognized for their leadership in bio-innovative drug research and development.

As stated by the Ernst & Young Fudan China Most Potential Enterprise Selection Jury, "the award-winning companies represent a creative, entrepreneurial, diversified and inclusive corporate paradigm in today’s highly disruptive business world".

Virogin’s CEO and co-founder, Chris Huang says: "For Virogin, this award is testament to the work of our core team, all whom possess extensive experience and deep background in technology development, clinical advancement and business operations. At present, the company has three independent R&D projects and ongoing cooperative research and development projects. Our clinical product VG161 will enter clinical phase in the first half of 2019. We look forward to continuing our R&D work, and strengthening relations with our strategic partners to advance our SynerlyticTM platform."